-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WYerN9XhpQtPDo5PWb9U1MiBi3VJaclE7XRX2ui/J84q7khRq8bAfynR3ya3Wbjl ksMKz/tWgAgse5Jo0rSA0w== 0000950103-04-000324.txt : 20040301 0000950103-04-000324.hdr.sgml : 20040301 20040301135450 ACCESSION NUMBER: 0000950103-04-000324 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20040301 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20040301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 04638480 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 mar0104-8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 1, 2004

Shire Pharmaceuticals Group plc
(Exact name of registrant as specified in its charter)

England and Wales
(State or other jurisdiction of incorporation)

0-29630 98-0359573
(Commission File Number) (I.R.S. Employer Identification No.)


Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code      44 1256 894 000

    
(Former name or former address, if changed since last report)


Item 5. Other Events

     Shire Pharmaceuticals Group plc has issued the press releases attached as Exhibit 99.1 and 99.2 and are incorporated by reference herein.

Item 7. Financial Statements and Exhibits

     (c) Exhibits.    The following exhibits are filed herewith:

99.1       Press Release dated March 1, 2004.

99.2       Press Release dated March 1, 2004.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

SHIRE PHARMACEUTICALS GROUP PLC

By:    /s/ A C Russell                  
       Name: Angus Russell
       Title:   Group Finance Director

 

Dated: March 1, 2004

EXHIBIT INDEX

Number      Description

99.1            Press Release dated March 1, 2004

99.2           Press Release dated March 1, 2004

EX-99.01 3 mar0104-ex9901.htm Untitled Document

EXHIBIT 99.1

 

Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com 

 

1 March 2004

 

Shire Pharmaceuticals Group plc (the “Company”)

The Company announces that it was notified on 27 February 2004 under Sections 198 to 202 of the Companies Act that FMR Corp. and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries, both being non-beneficial holders, held solely for investment purposes in aggregate 62,487,258 ordinary shares of £0.05p each in the capital of the Company. These holdings represent 13.05 per cent of the issued ordinary share capital of the Company.

T May

Company Secretary

 

For further information please contact:

Investor Relations

Cléa Rosenfeld           +44 1256 894 160

Notes to editors

Shire Pharmaceuticals Group plc

5

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently has a range of projects and products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com

6

GRAPHIC 4 exhibitsx5x1.jpg GRAPHIC begin 644 exhibitsx5x1.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_ MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`"M`0`#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@!#TZ$\C@'!ZCOD=.IYY''/2O+/%\7B MNQUO_A)O[>FL_!/AO0K[5]0T735B74=8U*S%Q,MM<33P2HNGO;K"`J26[B1) MVDD"%67U2H9X([F*2&55>*5&CE1E1UDC=2LD4B2*Z/'(C,CJRD%68<$YJX2Y M97:NMFK)Z75[7ZVV[,#YWMO#":9>0:FVB M:^UM%IVNZ9JZW]W9:C#!+<+%J$,@22%T^=())HUF^@H_&'AIO$/_``B2ZQ;2 M>(U@:XDTN(3S2Q1*`Q,LJQ-!"^QED$,TR3F,^8(R@+5YQXE\`3V%C8VW@'2; M.WU"?4EC_M'4M1O[R'PG;2B6*35/#ME?SW,-C>00R$)'IPLU#>6A._8Z^/:% MXYA\$SZDOA?PQ;7]E:OJ+?$UW>VNM>,+[1G=M8AL;YQ7 M2O=V\!,< MFVMI+_PB:W=OY23/?;;N\GOFA^TRVD%L?-CM?,(W!DF?R,*OINBZK'K>EZ;J MUNI2WU33[/48%=2)%BO+:*Y174GY65)D!&>?O#@C.A+`DP99,NC@J\;!61T9 M=K1NK*0R,/O*>&Z'@D'S:%9TIRC4I\T8RDI)I6DDTW%2:;3>J4EJKZ`?,?A3 MQ?XUNO%5Q''K4WB""VUS=K-@\FF+I=OX/UJ*2[T;7M+EACC=)-/11;WUO]IN MU9D<@'(+?2UEJ%EJ$"7-C=07=O(2J36TJSQ%E&67S$++N`Y()SC![C/B'Q+\ M`6<.C6B^&=`\C2FUJWO?&&D>&8;;3]3UK2ECN(RMN8UB-S)92S?:DLB_E2E= MK1E20U'X0^&=8TS7KS6I+>/3?#\WA^#2K*W&F/H%[JMW%=I.NJ:WH&/)L-6A MMXY+2XGBQ;W99'MY)`9,>G7^JXFE]8BJ="<()*E%1C%\MKMM64IR;NFM>5:W MW3M>[NM$MWJ^FE]_3[CZ)K-U=]133;Q])B@FU-+>=K&&YD:*WENEB<,44F1-+GO_`"Q_4TA`(P:\U7LKJSZK<1B>')]:GT+3)O$EI;6. MNR6JOJEI93M=6MOGU]1U%KZ]IO M@W0VU'7=3VV=A:QK+=WFPWE[,D*K&$CB$23WETZL3%"H)8CA`0:I)R:C%.4F MTE%*[;;2T7JT!U.X>YYQP">?<@8'OVI:^2]-^)OCO53J?Q,MFTI/`^BW3V=Y MX2:[B&IQZ9%<>7>ZO(F!,NI*0S01.R)<%66&&12'KZFTV_AU2PL]1MBYMKZU M@NX#)&8G,5P@D0/&Q8HX4CSSZ#KFH!8 MMDTND+"S/=`()B]E+!=R-$L<9D+X/ME(5#9!&0<<9..,]!V//4+ MI[K1Y;VYB=+6YU[2]+NEFGT.XO)0\4<-[#NBD?$^]U+3_``9>RG6=,&KP MZC=:5&MRDS:&-3;3M\EO`^I"T2ZNH;=I95]#\)>.]/\`%;W%K':WNFZC:VMA M?3:?>QPL[6&J*7L-0M+NTN+JQO;*X`(2>VGD0LKKDE37;D"1`'4$,%)7G&1A MAZ'@@?E7!"+PU:"JT(U'0G"HJ>(3G3DXV:C-1E%N+ZI22DGOM9-7ZM>C,71; MG4QI-@VOP65MK+VEJ^J6NDW-Q?Z=!J3VZ?;H-.NKK3]*O+FT2\6X6UGN=,L; MBXM_+N)[2UEDDMX=I7#=`>F>1]/?W_G7S7^T'\!=;^--[\(KG0OC7\7/@PGP MN^)VA?$;4HOA5JVFZ;!\1-/TA;R.X\">,X-2TC5(M0\-:FEU()K8%(4$DIFM M;AWMIK3TG5?BW\-/#_Q`\*?"?6O'WA72OB;X[TKQ#KO@[P+?:UI]MXK\2Z-X M6$(\0:CHNARRK?7]IH[7$7VMX86`VS[9I#9W:QGLG)TU0;JRE&O5K4:=&M*6 M&A2]Y.4[-"2,@%XF/E2%4\Q6V+C9#87+$%N^"!DYP`H]S@*.2>`23R<30O%/ MAOQ1'?3>'-?T37H=+U?4O#^I2Z+JUAJL=AKVC7#VNL:)>O8SSK::OI-U&]MJ M>FSF.]L+A&ANH8I%*B82EK4IR:Y'%.I#[#G\*[?5]!72LFU=[+OUT M[Z:GC7Q8\/>!;*>RUF^\*3:]XIU.=+'1=(TZ2\C77+ZW020?VK%;%+:6SM2R M&Y:[R[0ELLXW5H^$/&OB#29(M%^)<6B:+>2P-=6.I1ZIH6GV$J22JMOI,-@9 MQ<1W-M$?*#AGC=8OE\/SW=QI%]/9IJ5DIOX4M[VVO] M.D>%;NTN88U#QB>-E8$JV&;/?T40;I5'5IZ3;6OHDM;W5K+735:>H>;>!?AW MIW@N6ZOU:.?6M7@@35)H#+!8+)`TDKQ:1I\LD_\`9^G-*[2162S2):Y\N)M@ M`'I"X```P,#`]!C@5S/BW1=1U[26T_2]=O?#MV;FSG&HV"P-.([>X626W(F5 MAY=PBF-R,'GC/0ZDNI6EI)9VMW>VT-S>2&VM4GFCAGO+E$,AC@B?:97,2/(0 M@YP=HZ4Y2E4DYS;#/']_H5A/XJ\,Z/XFCMX=BV M$/\`:.HF[]40[AG.>>V,=`1T^N1^!IQ4,,'IG/XCI^74>]3&5>#G*E6G2E*$ MZ?/3E*$O958\E6G+E:YHS@Y1<6[24G&2M>X?S=?\%9?V_/VH+OQUX[_8+_8+ M\%^+V^-&A?"K6/B+\:?BEI/A[6/$5[X1\`S:$=0L]%^'D/@B#Q+KNA>,?$HG M.GVGB;7]/TD_GC_P`$X/C_`/#7X&_M8?L._"O]@_XA M?%+X@^`/VM_!>O/^V=\'?BQK7ACQ=JGA?XD^%]$O+O5OC#-:^#->\4WGPU\; MQ7=IJEQXFT:_LM.TW4?#VA6O_"1WMQ>ZC)=/\-_"_Q'X'DL?$VH>%[-;1+KQ_XDU+6M"OOM8DTBXU'1A9PIXH_2^& M\ZRJOE\^'IY5@LMPDL%6>/S'&XRG4PV*Q$Z,J,,9F-)85XS$_4L0Z%?*\'@8 MUJ\<2XQ@H+VE5^3BJ$J^.6O^.O$OPUT#XC_ M``J^%/QO\*?LW_$SQ#HM[Y6B:#X,^(WQ-\.6NE7WCG4]'-I?WFF+JD6G:G=W M93PM)J-J89W_`&TB=F!W$9R<#&TX#,OS+G(.5(/49'!/('P>8Y7C\IQ#PN88 M3$8:HG)TI5J%6A#$0A/EC7PZK0A.=&;7-"7*N6SA44*D7!>E3K0K1YH24E]J MS3Y96NXMI[J^MKGS'K'@:W^'TFE:OKEY!KO@S1$G\-V>CQZ3;?VQZM[ M.VT[4KMIK:VO=/TJZE2ZMC(IN$9-R,)&+&7PK\1/&5MXS?0?$$<6HPR^*IO# M5UI]AI8M1H`GTVYUC1]1BN!MNI;&XLK2>UFCU"&%4FA1K22X5Y6B^AM;T;3] M=TZYTS5+:.[LKM/+N()55E*C!#(6*F.6-U5XI48212*KH00*XSPOX%\/^!FU MG5X]0U*ZDOH+07FHZ_J)O'M['38VC@B^T2)&$BB1FY;I`//0'OT/2I`0PR"", MD9!R."1U'<$8(['([5\K>(?B?J'CC7K#PWX,UH^%=#ENI$'C"_MYHEU?5+!R MPTK2GPT+QS,/F64QO=103R1,J1,C>M_#OQK>>)HM7TO5DMEU[PO>IIVLW&F, ML^C7TTAD:*[TRX"JS1S(-\L3(KPR*RD%2&,5L)7H4O:U8J&CBN'*DK&YSM*'HZUN7VH6FG6D]]>3Q6]I:QO+?7+>H;U[D#/J.#D9%?/WQ!\%_$/Q[J.JZ9/=Z;HWA+3K M>&?0XX&FFG\1:D\;#[)K8@D66*PB)9)$2,1AF28>1>;&HN(MZ@20.CKG=M')_&WX9V_P`8O@[\5/A)>ZO?:#:_%'X<^-OAQVH,D;"6`>7)&QW5Y?X?AU7PWXO MT/7M?T?0?AEI%IIJ^']61-=LI['Q-C/Y//&W_!/76?V;YOV= M-2^,GC?X2?L_^!/#OQ[_`&9--T7X9?L]:YXZUOP+^VI^T!\+DN;WX+W6J?"_ MQ5X%TO1?V>OBMXOUCP[9:1XO^(V@^,_&^C:_:7VK_P#"5:=/FN M=6\9_!?X]^&_&OAK0[GPWXQN_!`@\8>&M9T_5+C2=6T^Y$3Z1IQ(E/ZQ?M#_ M`+/OPY_:9^&&M?"OXDZ=J3Z)J%[I6N:5KN@:C/HOB_P;XN\.:A:ZQX5\=>!O M$5NDEWX<\7^&-9LK34]%UBS5VCFCD@N(;NQN[VSNOYLOVV_@KXI_8$T'XT?! M/X9_%[XDZ!;_`+=?@'XD_%#Q%^W;\=/B9'H_B71OVD?A9-IWB/PW\*SX\\)^ M$?!_@OX9P_%KP,?%O@N#7)VT37]=U#Q25T34KJ?0(]`O/T7*\?@^,J%3+\UC M3Q'$%;ZPLNJU:5:G##NM4C5Q&,IU\.XSKITYRQF,HXB%?%5JN!H8/!WH5I0I M^1.G/!24Z-_J\;.:LEV_=\O]YVAS:-*3DVFKO^K^*;=L3`!V\C.&7;QED*+@ M-V(^7L.,475M'=Q26\\<4T$J-'+#-&)8I8WP)(Y8F^22-TR"K=\'ID5^)'_! M%WQQ\>?'_P`)I?&NL>)O&'C#]DSQ?X!^''B#X`:M\:?%5WXM^/?ACQ]CQ!X: M^/7PZ\4^(M1TS3M1\4^`M`\=>'/[0^&'BG5Y];U'6?"^NZ?)_;MQ(M[INE?L MN_C7P?#XIM?`UQXL\-0^-[[1KCQ'9>#I==TJ+Q5>>';2]@TRZUZU\//=+JUQ MHMMJ5U;:?<:I#9O8PWUQ!:23K/+'&WP.9Y=4RO'XK`3K4\3+#2DI5*2:2C&* MQJXG?WGU6K;N>=^/O MA]=:UH>B^#_#5IHNA^&5OHI]7EBB<36%K;2-=*NFV<+0QG[6Z,LT@D$P\S`9 MD,@;R[3/B5:^$K*\E\-^"]`T3P@LUU=Z4E[+<6.I>,4T_47T[49])O1;R6C: MG;2Q.XTZ]#W!C+A)4117UKE'("M&K@`@C&2G3&.I7)''W>1Q7C?BCX::=8V. MMZGH>AW'B*YN9C?V_@R]U!!X8DU2>XADFOX;*Y0BTF$C2W,L5M3"<^$Q-.K3C2K\U2E*2YH3D[7:UV4445 MS@%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!37)` M!'7(]<=\Y`(SQG&>`<'!Q3J,`]1FAJ^X'@/C/P;I=H?%7CSXAW,OB_2](AEN M/#>A^4UG:Z+8L($6SBMX)DCN]1N+QA$M](Z.%"2;4+^7'R/@7X@ZSH%QH>@: MII&GZ?I>H:K;Z;I^@G4]6NO$VE6VK1R7^EZL9M2DN4UW2+A))(VN+!HDMFA> M.6)&PE?4%_866HV5U87]I;7MG>026]U:7<*3VUS#(NUXIXG5DDC<<,K`@CW` MKP?Q9X>T[P!;:9JMAI]S>6+:K;:;>!])O;>:R;4=`,B3W&FVUG M+);/<;96@B2/S2$`9V[:%>%1?5JSQC=VBUI>S=E[SN[+FEYO1A[]G"1H M%(R%&.%V@`=CMSCIA1D=ACIS'B_P3X/\?:'?>%O'?ACP]XS\,:K'$FJ>&O%6 MAZ9XAT#4X[>=+F!+_2-7MKRPO%@N4CN(5N;>1(YHXY4"R(K#YX^&'B&ZT2PD M\1ZEXAE'A+3(KW0?$;WVIZAK5K<>(;"\C_LW6]"=X[FXD36K*Y`N;>V?8+E! MMM@0HKZ:T37M(\0Z=#JVD7T%_8S?DE\U==K[ MZ'P-^WG\9?CK^S+\!?#^F_L=_LXZO\8_BSXVU_2?A-\.-`\+:1;Q>!?A9+J& MF74>E^,O&EC:-8#3/!&@1:>UO%!%]BT."Z:UCU;5M)TA;F9_Y@OC%\-OB?\` MLQ^/OCAKO[77_#1'CK_@J]XHTK3_`(U?L6_M3?LZZ]KWQ"T'Q-::?91>&I_A M]!\-=#T'2]*\(^"?">MZM=Z-\0]!\7>"G\/:SX5U99/"MKI%FL=GJ_\`?X?`XJ.4RP6&C4S*K&$\95K3I8C M,L97Q%*&#P>*S"JJRP654Y2G/,:%.E*./PTJE&LIR5*WEX["\\)3@W%4H6A3 M^+#TDVKU70]WGJI74)*2Y79Z6/U=_8]\1_&WQ9^S-\#O$_[2/AZ'PM\>-=^& MGAO4OBAH$%HM@-,\53V437D4^GQ3RP:5=W*,M[?:3;[K;3=1FOK&W%M':I;) M].J"1S7\EG_!/KXO_M%_"_\`:_\`AUH&J_M2^-OVCOV:X?A[\?/%_P"T M1^TCKWQWOOC-^S)XD\#Z5I>GZ[\(_B3I7B#Q9J&H7?[/_P`:=-UG4[+PA\4/ M@G/K-E!HFCG0?$=I:ZGI>N/JNG?N3^Q-^W5:?MQ:E\7_`!3\-OA=XTTC]G;P M;XBTOPW\(_CYXEDCT?2OCQ/;6ZP^-K[PSX/U&*Q\1Z9I?AG6X)+&'5;JVN+' M58KE5D?3]7@O]&T_P,_X:#;+K5AJ'A]M%/AM=1721I>IPWBWVD>)=*E>)K,7=C=I&UPAA$K1K ML2<<5VG@GP\/#&G7>K:Q.J:YK,-IJ/BV=KO?I_\`:EM9I#=WD0>-$M]ZPJ]R MXD9)&5G[@UZ17GGQ`\&WOC6TL=*CUZ?2=(:ZC;7;.V@C,FJV2-YJ0?:CF2+R MYD4B(JT$RN_G!MJ"NCZQ*I3HT*LH4J<96J5E"4JDH-JRLGK)/E47%1NU%2O: MX&%:?&CPM=^(9M)7S4T=)$L8?%S[U\/7.M-ACI4=ZT0@$@C.Y)WG5)7'EJ@R M&KU7R8[E6,A65&!",I!4JZ$;T.WY2RR.N59E:,@Y*N5KXUUC3$:X\8_#WPQX MBM-/^'6G1V=SKM[XDM9)[;P[J:ZA;/R01P)!#9XY?+P)(4 M:$/P7W9)TQ.&HTXTI4?K#<;RO*\H^S:C[.=248Q5.HWS?NY*\=&GJFQI/<_- M7]NK_@GEX>_:3U;P3KOBKQ5XLNOV;OA#I'B[XC^+?V/?`%E8^&=%_:"^+6D+ M!K7@K4/%'B+1%L]5U"W3[%-HEYH6H6^H"Y^U:>^CW6CE]5.J?S\?#/\`;P_; MZ\-^#_#GQI\.^._$/B#QOKNM^`(?@U^R1\`/A[X.\9_LT6>C7'CH?#OQ!^RE M\1OA#X?\+Q?%C]FGXJ:/;6][K7A/Q;K^LK;:[;6<.F:;%;36],O/$_A&/XK?8;>[T/5M?T_3K..TU_ M4KQ!#/81Q7>HVD6+POU7$9G"G+`X&,J\98N6 M(56C5<(8J+C+&8^A3GC72H1H0G'F4Z?F8K"U(MXC#3JPG!-PI49--O2\8KF4 M4G9^Y)JF]VFU$_5&BBBOA3TPHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`II4$Y.:=12DN96]/P=_T`\K^)7@:7Q7H M4=CI\=@\T/B#3M>N+&]3R;+6AIX96L+Z2"/&H]:M=3DLF@T[7[G0[[1;#7Q!OOM/CO$DXBFC:*X2)9 MF64B*9'R&V,C,2W5AL;5IVP]1JKATW*.QSR3FOBF+P9>>';+3QK8M/`6D:/KNA7VI:YK=Q M;WZ7%_97$OVN]\,ZPD\.IK'X@6",76EW]H\4*;YH)B?,1_H30/B=I^L:M9Z9 M-I\^FV^L/>?\(QJIN;.]T;Q+'8,#/_9M[93S*LZPXG^RW"13`%T=%D1U&V*P MZ:=3#2=9)U%+W%%)4W&*:LVFFO>M%R<8J\G;5AZGO7U_0_X4;U]?T/\`A4-% M<`$V]?7]#_A2-*BC+-@9QT)Y_`5%7SO^TW^U1\$?V//A%XD^.?[0?C;3_`/P M[\+QP&ZO[D2WNL:I?WCQ0V6A>&?#EI%+K/B7Q#?33!;71M%L[V\:));J2..V M@N)8;I4:V(J4Z&&I5*^(K3A2H4*-.56K6JU)*-.G3IP]Z^ M*OC#2/`45[*RIY,UKX/\':=X_P!4U)[EGVVMBVN:9J$@RDMM%.)8(?G#5/\` M@Z:_;3^'\BW'Q/\`V,_@1H::F+I=,\)77C7QMX7\?6OE",1W>N^';^XUO7-- MM'::.2VEUKP_X>M]7MR\NCW-U''-)!^@T_";Q"JQHM9`H2K1YX4L5F658"M. M+Y6G'#XK'0K*U[.\&[V;44T?+SXUX:@JD_[1E4ITY-_C1=#P]J4\SBVEO=;T+3/#$>U-0N-4L;62XM+#^A>#X5_\ M%F_A-/9>,O#G[8G[,O[9^CVODWVL?"KXH?L\V_[.FI^)-)MRTT^G>"/BE\*_ M%'BJRT+7]4B:.+2=0\4>%-7\.1RO!)=[;1GN'\_/.!\RXLXKF?3E_$6%S6,JV74JV M,PD9N,Z]/V,)4DG:]7#RKO%13TLY4(RN_>A&SM^TF]#UP#Z>A%)YB M9QGGZ'Z^E?#GQ)_;L^&/P=_8@N?VZOB!X4^(%K\.=$^'7A/Q_P"(_!6AZ;H> MI?$?1%\2:GH.@W7AM],O]:T'0[C6_#6O:\FF:XG]O6UJAL-0EL)KL)##/^-T M'_!UM_P3CNKF*VB^&?[7RR7%Q!;123?#3X8+;[[F=($9I$^-010RR M)&C,$9MJOY66\)<5YSA\7C,IR',,QP>"KU,+BJ^$H1J4Z6)I1ISJ4)SE6@E4 MA"M2D[1E%QJ0DI>]RQZ\9GF59?.C#&8W#X:>(C&=&%:JZC5G;F?].N]3W_`$/^%&]?7]#_`(51M+A+NUMKJ,,L=S;PW"*X"N$FC610 MX!(#!6`8`D`Y`)ZU8KP6FFU)---II[IK1I^:>C/5332::::336J:>J:?8FWK MZ]?8_P"%&]>>>F,\'N<#MW-0]B?09_E_C7Q7^W=^W5\(_P#@GK\"YOV@?C9H MGCW7?!$'B[PQX+>Q^'&E:%K?B1M4\4_;CI\ZZ?X@\2>%=/-C%_9MQ]KE?5DE MCS'Y5O/O.W3#8;%X[%X;`8'#U,5C,;6]AA:-&#G.=645[./*M9.4[QLFMX]; MWRKXBEAJ=6M7G&G1H4G6JU).T84TTG*3L[16[>MEKZ_;@(/(IN]?7]#_`(5_ M.1\(/^#G']@#XU_%GX7_``9\)?#O]JJR\5?%GX@>#OAMX;O=>^'_`,-+30;3 M7O&_B'3O#.CS:S=Z;\8]6O;73TU'4[+IJG*K2A+D=2FN9MQYM+ MVLFK7.;`9G@OK^A_P`*AHH`FWKZ_H?\*-Z^OZ'_``J&B@";>OK^ MA_PI0P/0_P`Z@IZ=3]/ZB@"6BBB@`HHHH`****5E>]E?OU^\#D/&'A'3?&&F M6MAJ+W$366I6.JV5U;A))K74+!G:UG$4L%S!.J,[!X[B%XWC=U+(6#CP&[\, M3>&/$?\`:%\T.J_$773XAG\$Q0V*Z=X7LKO2;=8X7DM8A:0MK.JZ<\LTLF\Q M/QQ[]:YWQ#X7T;Q3:+8Z[90W]M'/'_X^_\`!1__ M`(*G:;^R?JOAG]FW]G;P;:_M(?M]?&&>STSX-_L^Z2T]Y8V,U]J"P)XH^*U_ MI=Y!+X6\,V=A'=ZFMI<7FFZAJ=G:7>I-=:+X";* M7^SK2XU3[==:GXAUQK*^O[;P_P"%]"TN&ZUKQ%K][:6-Y=P:9I5G/,+*UGU* M=H-,L[R[A_B?_P""K7C'Q[_P49U'PM^UG^U5KGC/]A+]@/P5X:B@_9D^%GQ& MLM/\2?M*?M*Z_J/VO4=:\9?";]GJU\26UI M7%EI=U^S5^S8+KR[G3=&^%'@":Q.GW?B70+7[.ESXWOX\-J'GZE;PW6L6D7B MW4?QC_X.7O\`@E]\=?&WQ"M?V]_@M9^+?BEX/M?!FE^%OC1X#M[K5/%FO?#U M-!N4L-$\7>`_!L5E?O-X+U"P=CXUL]$MC+HVKV9\1_8;S3]8U672_P!6\.*G M"V7<59=@89M1EF&(I8JC5XCG0HO!X;$VC&&$X?ABZ5[I--U*YQ&W\1'@GQKXV M^&7BG3_&GPZ\7^*OA]XST*Y:32/%'@KQ%K'A?Q%I$\,\S&33]6T6ZL;_`$Z4 MEVBG^RW$;36RI97;26ZM;C]M?@A_P)+R_SAQ=Y%?MW%?"GB%0S& MEFG`W$M##X)4,/*>79A7E/$XK%4VI5:\L?B,-CI9A'$*4HTUB<93^KP2ITZ5 M*#BC\[R?.^&ZN&EE^?9;7J8IJ4/;8>G&-*A?2"AA88F@J/);=0G.J_>J?#K^ M0'B;X!_&KPIXE\0>$M9^%_Q"DU3PUKFI^'-3^S>"O%%[:-?:'?SZ;=+;74&C MA+ZT2YMI%M;F%-MS`([B-1YE?Z&'_!MO^T3\:/C'^POJGPG^->B^*+#Q+^S) MXV7X8^%==\7:=K.F:QK?PWU#2+?Q%X+M;W^V=/M3=2>#O/U/P=:O9B\MH]"T MC1HY9GOH)L_GM^R)_P`'8O@KQ#KSN600?%'X(7.K^+/#MH\ MFQ9?[>\`^)+Z?Q)96$#.TJ7?A_Q-XPO;B/\`T6+0TG6-;C^MWX._%SX:_';X M>>&/BO\`"'QGX=^(/P[\:Z5;:UX9\7>%[Q+[2M5L+DRVIN'-%./-RQ?VO!>4950Q=7&Y1GD\7&G2G1Q&!EA MZ5"4(5)\]-54GS\]*3BN92FWRN+DU=GY4?\`!;3P?I7@3_@BY^UKX/TA#_9W MAWX5^`M,ADDC@6:[DM?BC\/1<:A=K"B0B\OKKSKZ[>!%62]N9Y@N9&:O\O[3 M\1ZEIY&%1-4TU2%(&U#=*P!5>0FX;NFWO_`)1%?MK_`/8@ M^$?_`%;'P_K_`"S8I7@N(YX]OF6\Z3Q%XXY%$D3Q2IN61661"\:%HI`T4BJ4 M=&1G5OM_`2$J_!>=T8I2G5X@QE-*;M%RJY-@%3YI.Z45*-W)Z1T?I\OXG?\` M(_RG7EC#!863MI9+,,1*32[\D)7VOM?4_P!>_P".O[&1^TI^T% M\,O@[?:SHD%[HVB>+?$D$'B?6+"VA\F?4M+\*60O/$FH:?'-#)"]Y9Z3-:K. MI@\XRX2O,_@I_P`%6_\`@G/^T5XQTCX=_"']K_X->*/'GB"ZCL?#O@V;7KOP MMXH\17\W,&GZ!H?C"S\/ZEKE_<`$066EV]U=3L"L,+L"!_!?H_\`P1__`."O M'_!130]2_;5\1>#AXLO_`(LK=^+M&NOBM\5-(\*^+_%^D7@-WHTGA?P[K-ZT M>B^$#!,D'@W3M6B\/V5GICA-%L;:RN6N;S\5O&_@SQE\,?&?B3P#X\T+6/"/ MCKP/XCU/0/$_AW6H#8ZSX>\2Z#>W&FW]C>P)<3K'CF&%PW&OUWB#`\WUZCE\*%3`82O.9'52!W+.G.>P)8%AC)P2/R<_X++?LV?!K]J[]CRX^$_QY_:?\ M'?LB^`6^*7@'Q,_Q;\$_P#!TBJK_P`$N[K"K^]_:$^#H;*JV-A\3LN"P)ZK@@D@JSJ1AVS^29!D M^89=XAX#(%BW@,QP/$N'RV./P\*>(=&O3Q"IQQ-&EB8NE--3A.$:D;2NE44; M-+[G&YCA,7POC,S>'>(PN(RNMB'AJCY'5IRIQ_=RE%IQ2E=-IWMJM=#\@OV8 M?^"-O_!.3X=?M+?L[_$#P;_P6N_9R^*'B_P)\2I88`4A2X;_7N508V4]"`V>."RY(`QM`'8;>,_3'VOC?EV9Y= MFF0PS3B#&Y_6J97B7AZ^-P>`PE3!TWC(Q]@HX&,:=12G>HY2YK?#>UDO#\/\ M9A<9@,?]0RZAE=*EC*,98>E5K5U4;@G*3E6;4;]%%^O=?'7BS_@HA^P;X#\4 M>(/!7C?]LW]E_P`(^,/"FK7N@^)O"_B3XZ_#;1=?\/ZWIEP]OJ&DZQHVH^([ M>^L-0L[B-X+FTNK>.:&1&CD0$$5ZOX=_:>_9T\8?"C5?CMX4^.OPC\2_!;08 M=:GUSXLZ)\0/"NI_#G1X?#L\EKKTNI^,K+4Y?#UDFD7,$UM?FYOX_LMQ%)!+ MME5DK_*__P""JJ@?\%*_V\,`$M^U;\;R2R))R?'FLDD>8K8[?*N!P,@GFN6\ M">+OVOOVJ/AE\&/V#O@YX:^(7Q(\&^`=>\8^*/"WPB^&^F:MJ9USQ7XY\02: MKJ_C?QO%97#0F#3$O;'2=-UG7!:^%_"U@#=17%K=ZI>7C?0+P(P,\FRC-*?$ MRHTL7#"XK-GC,/2I4,%@Z^"^L572J6YZ]95>2E3]I[./O.;GRPY9>.O$G$0Q MN,P<\J5:K3K8JE@X8>=6)$U74[S1]&"MJNI6)BA%K?V-@K MH;JYM+B:*,.F7RZ@_:V]5RI8$]@"23@$GG+'@`DXSP"3WQ_"A_P0H_X)@?M^ M?L@_\%&/`GQ-_:,_9P\3_#?X?W'PG^*VF3^,GUWP'XBT?3]7UG1=+&EZ7?WO M@_Q-K4UG=:DT16&/44TUI[A)B5:0+(_WQ_P<1_\`!8KQ[^R)I/ M"GQO\;>&#XG^+7Q$L;6&75_AU\/M=AN;#P_HGA"\FFE@TSQIXP:*_P!2FU@V MDE[X7\.VVGW6EF'5]?L=3T7\_P`U\/X5N-<#PGPAF<,ZAB\OPF*EF-65"5## MR?MWBY59X7VB5"BJ%I1K ME[)6Q"C*7Q+WHNUE-N]M/WV_:"_X*"_L4?LJZG'H7[0G[37PA^%WB.>! M;J+PEKWBNSG\:/:D1D72>#=+_M'Q4UL1-$PG&D>44D1]Y1E)\5^'7_!8O_@F M)\5?$5EX5\&?MI_!2?7M3N/LFG6'B'7-0\#F^NG=8X[:TN/'&F^'+2XGE=U6 M&.*=GE)'E!^$7USQIINH>#+S4Y+?2FUFV\2(]IJ6I:9;ZAI<$$_P!OA^]EX3\! M9?FV&X6S7CC%4.)\9'#QIT*>'H/"4Z^)I1J4X2E*E-0A5?-[*%6O2K\LH1<% M-\LOFX\8\2XO"_VMA,AI3RBE*4JDE7;KSI0LW-P]JDDO=6 MUS#;RV\T.6*528Y(I8\212HS)+'EHV=*M7\9_L]_'#Q-9>#_``!<^)=Q^'=9\.NL5II6JS:)K6EV^GSPZK8ZA_H;V[% MP2?O`+DJ/D!9$?`.3NP&'S#@CL#D#\EXSX/S+@K-5EN8!OV?/#\,%AJ3:=KT=E'%JWQ#U'1KJ4RZMI'@B74-+2 M#3+>TO3KOBC5_#NB2PG2;C7+W3>%_P""0?\`P2WN/V7]`D_:W_:ADU#XC_\` M!0;]H2PNO&'QC^(?C>\37O$WP]C\80VEU<_#;1K^$/IL&J6D$5M:^-]=T]6& MJZE;MHFCW$?A#2=+LY/YV_\`@L?\0D\!_P#!PG^SSXT_:,^V1?`/X:>+/V0_ M$/A^?7X;RY\,VOPMTG7O#OB/QOJME9&Y^Q3VNC^,&\9W/B=+>&662.PN'U.* M:V738[7^\_PCXP\(>._#VE>*_!'B7P[XM\,ZU:0WVD:_X6UG3-=T/4K2XB26 M*YL-4T>ZO-.O8'B9&CFMKB:(HP*.58$_J6?8.KPQP/PWA,`N?_7+`RSK.\UH MJ2EB*+J\F$R.55:TJ.'A'VF,P\9*.)JR@ZBY(J#^.RZO2S?B'-,17?NY)B(8 M+`X2JXM4ZRI1>(QJB])NI)QC2DT^2S?,^B'R$_?8A<\$\#`&`>#U!STP" M.N37\^_Q'_X.6?\`@G#\+_B!X\^&/BRU_:)MO%/P\\:>*/`OB6*V^$=K MO^#?$&H^'-;6VF?QA;2O!#JVEW4<+RQVD[;$9X(FW(/WKU[Q3X9\-I"WB'Q) MH?A];MC%;2:SJFFZ:L\F&_=VS:A=6PGFX)\J(2L<<)S7^=3_`,'$G_!-+XB_ MLS?M5_$#]K'PEX?O]>_9S_:-\37/C>_\4:9ITTVG_#/XI:^T=QXP\*>*;BW5 M[;2;;Q;KOVWQAX9U&Z6.WU:?5]6TJWNH9M#%M>8^%O#_``QQ'GM;)N)*F(P[ MQ6&YLHG1K+#PEBZ5IU*$O=M.5:BW*DHVLX*,4VU9\79CG.4Y?3QF40IU%2KM MXQSCS)49M6E>TFG%J\IZ6CTT1_19\$_`7_!$/_@N=>_&7QEX._9AMKWQSX!U M7P[+\0O%=YX7U+X#?$;4;SQI::U-H^MS:E\+_&&GW_BI)KC0=26?4/$?VNW- MU;O#(EQ(DLT7SE^TS_P:=_LT>+--GU/]E7XX?$7X,>*D\^YAT3XDK;_%;P#= M,I#1VD3VUKX>\::(!DQ#49]7\5-"CY-A<.41_P".[]B']O/]HW_@GU\7&^+? M[.?BZTT75-4T^'1/&/A77=(/B+P7X]\.P737<>B>*M`\^Q:YCANV9].U/3=4 MTOQ#HDDUZ^DZE:QZA?QW'[A^)_\`@["_;RU[PQ>Z5HWP2_9C\):[=V%U;#Q? M8Z!\1];GTJ>6)H1J>E^'M8^(=QI;7L$D@DMK369-6LL*1?1?%/AO5M'\0:1]IAL=5CL]2AAU/3-.U&.YLK?^K?_@T9^-7B^+Q3^UQ^ MSU>7]U=^`;7PUX&^+^A:069K#P_XG_M>[\)^)KG38)7=[8^)-+E\,17L<;F. M63PQ8R2+Y\ES/-_(M\7?B_\`$S]H#XF^+?B_\8?&>M?$3XF^/]9;5?%/BO7+ MA;G4=9U)XX;6&)8HEL[:UL[*TM[73='T:RM[+3]&TRTLM)TVUL[*SMX8_P"\ MK_@V$_X)_?$_]F?X)_%G]ICXU>&KGPAXH_:6'@:U^'7AC6(I+3Q+I/PI\*1Z MY?1ZUKMC+#;76B3^-]>UXWEOI-[%'?MH7ASP]K%Q;V8U@6J?4>+.)IX/PTQ. M%SVOAZF<8Q97AH>P3A2KYSAZV"KXVMA:&G3P,*N+FZDN9.&!GA\12H4<1'[=6$I48MS;DII/XD?I'_`,%ZQ_QJ M(_;6.6EI-DPW5_;VMRFT?O+:ZDCAFB#Y! M43)N60@9V`QC(E8I_J7_`/!>LJ/^"1/[:J!@0/`/A'D_MS'WDMDUD M>7V>VC4I.U^K^1W^)[7^L.5Q3T>"PL9>499C7BVMK>Y4EKT>O0_V@O#>F6.E M^&/#ND:=`EGINEZ'HEC8V<(VPVMI865K%:6L"DDK!##!%"BDEA&H!+=_\M#_ M`(+D6L-G_P`%9/VVH8(HXE?XFZ'=.L2[5:XO?AMX'O+N8@\E[BZGFN)"?^6D MK`9`!/\`J?:41_9.F28JHTEO-9O@E=]6[-K6[MU/I?$N$?[!RY7T_ MM&A!*ZMRRPM6#MVM&G';32[N?U5_\&DP_P",#OCYZ_\`#7'B/\O^%.?!X?U% M>U?\'27_`"B[F_[.%^$'\O%5>*?\&DS*/V#OCX"R@G]K;Q(1D@9'_"G?@WR/ M4&Z;W_U?J7\G;;R/X/O^"?7_`"?S^Q#_`-G;?LY? M^KD\$U_KXI]T_P"XO_H%?Y!W_!/H$?M]?L0Y&/\`C+7]G,\^B_&/P2S'Z``D MGL`2>*_U\5("G)Q\B]?]RO;^D7_R.^&_^Q5B/_5@CA\*_P#<,V_[#J/_`*:B M?Y*/_!5;_E)7^W?_`-G6_&[_`-3O6*_LC_X-3_@U\/?#_P"PQ\0?C9IGAK3H M?B7\2?CCXO\`#'BSQ>R%]8OO"W@33O#P\+^&TF8;8=(TK4-;U_5H((A'YE]K ME]-=?:)%@D3^-S_@JL#_`,/*_P!N_@_\G6_&X_A_PG>L<_3@U_;O_P`&M/'_ M``3"E!X(_:,^+^1W&;;P81D=1D,O:-*4>JDNC6SU6I_1R4R M`O;Z^^>1CG\Q7^61_P`%X]3\4ZE_P5F_;('BQ[@W=CXU\(:=I*3'`C\+6?PJ M\!Q>%$C3RX]D)T(V9=\CLYPKR?ZG5?Q+?\`!SW_`,$SO&6L>+=,_P"" MAWP=T#6?%.GWFB:%X%_:)\/:%I7V^]\.IX7M%LO!_P`694M$-Y/H;:+$_A/Q MI?RQM:Z#:Z'X4OO]%L]0U'4;#\E\$<\P&1\82IXV<*#S7+,1EF$Q#4$J>)J5 M:%6G3DVH_NZOLG&2YDG+EC9\RM]MXAY?B<9D,JF%A4K/"8B&)JTE.;YJ:A*G M.5O?ORQDY:1>J3^RK?AO_P`$X-<_X+&:/\-_B"/^":%I\9I?AO<>/H#\29_A M1X6^'NNV'_"P8/#VCLL6N7/BG1M0U2'5X_"S^')(((IX[4:<]K/'!*XE*_:' MQ?\`#7_!S9\=_AKXN^$/Q<\"?M6^/OAMX]TQM#\7>$-9\!?"B+3=WE- MI=3V'ARRO[=$NHK:[\ZRO+6X0VRD3HNZOA__`()0_P#!73XM_P#!+OQMXPGT M+PI:?%WX*_$P:=?>/_A/J&KR>&)6UK15FM])\7^%/%":?X@'A_Q%;6$\FGW] MI=:1J6G:SHT]I_:D-M+IVDZPOZK_`+;_`/P=-_%?XW?"F]^&W[)7P?U_]FKQ M'KS64>L_&+4O'>G^*O&ND6MI.MU?Z/X&TG3/#%IING7&I+`MA=^+;R_GO+'3 MY;W^S=%AU":UN[?]QS]<80XJ<-,_P""0'_!6'P_?Z=XCT/]B;X^:?K>AWUEK>D7 MR:'I<<]CK&EW,>H6%ZIGU<1A[6^@BN/WF4;R\$NI!/\`JJ^$;G4KOPWHESK$ M30ZO<:3IL^J0LJ*8-1DL+9KRW?8S*9(;@R1N5)7*D`X`%?P"?\$;_C=_P5Y_ MX*&?M7^"]+N/VN_VA[S]G+X6>)?#_B[]H3Q+?^)TL=$?PUI^IF^A^'%G=P6< M37^O_$!K$:*-,T^6"_TS1IM=UB::WM],@N9_]!*U4K@9!'EKDEV+LVU/F*EB M,8PNX@M\H4';@#\:\:\SS;$YIE.69Y5X?JX_+'IXSZIRT<;/% MI5%4E&A&M3IS?/"-7FMR5(L^\\/L'@:.$QN-R^GFE/#8VK2@GF"H*5:5%2<: MU.-&1N@)^*/`__!%;_@F-\.M:;7?"'[)7@S1;U[C[2\0\5?$O M4=(F& MPU27/+#4,=B:.'3Y5%VHTJD(:VN[IN[>NIRU,#@:U15JV"PE6JHJ*J5<-1G. MR=T^:4'*Z?G;R/(?`?P&^#?PL4#X8?"GX:_#EBOES/X*\$>'?#99656D#L,UW_B+PSH/BS1K_PYXFT32?$?A[5[>6RUC0]= MTZRU;2-4L9E*RV>H:9J$-Q8WMM,,++!=6\T+KPR'@C?HKBZ>J.B,*<(>SA3IQ@TXN$:<(Q:?1I))KM>]MMC\+ M?C+_`,&Y_P#P2O\`C)XPU'QN_P`#-;^&6JZM<376I:?\(/B!XD\#>%KF>?YI M'M/!L5S?^$]!!D_>>7X'I4Z%+BG/%3I+EIQEF.(GRQ5D MHIRFW9)))7LEH>14X=R"K)SJ9-ELI-MMO"TM6W=NR25V]WN^I^7'[)7_``1M M_P"">G[%NJCQ1\'?@!HFH>/4DADM/B+\3KZ\^)WC323`8VA/AW4_%[ZE:^%' MB>-9#-X6L-&N;EU1KR:>1?,K]/8X2@/R\DY)RF3R>NQ5!..2Y!=B<,QP*M45 MX6/S/,CA*2_Y=8>G"E!V5ES*,4VUO=N]];ZN_E_Q@^#GPU^/OPV\5?"#XQ>#-'^ M(/PU\;6EK8>*O!VO))+I&MVEEJ5EJ]I#>1P302E;?4].L;V+9*A6>VB8D@%3 M^?L/_!$W_@E?#=9SEU&>'R_-\TP&&JSE4JX?!X_%86A5J2C"$JE2E0JPA.;A3A M%SDG)QA&+=HI)5\#@L5.%3$X3#5ZE-6C.M0I59*.K45*<9-13DY)*RYFWU*, M=J(XHX4B5(XHXXHT5MJ1HB;`HP&!"``*K(RG`!&.1^?WQ6_X)1_\$\?CE\1/ M%GQ9^+W[)GPJ\?\`Q(\;7\&I>*?&'B"PU&?5]=O;:QL]*M[J^D@U.WA,L>FZ M?96RB.&)%2W0!<@D_H?16&"S#,<)4YU\%BJV%K3IRDIRA.K M0G3G*#FN=Q;<7+5IM*U5L)A<0H1Q&'HXB-.4IQA7I4ZL+R5G[LXM62T5K-+2 MY\Z?LY_LH?L^?LD^$M9\"_LX?"CPM\(?"&O^()_%>K^'_"45S;V%_P");G3M M,TBXUB9+FXN7-U-INCZ;:LPE11':1@1\L3I?'_\`9K^"7[4_@4?##]H7X9^& M_BM\/O[9TSQ$?"WBJ.:XTMM;TA;A-.U$PVT]M)]ILDN9UA8RD?OY"PR$V^\T M4GCL>\9_:+S#'/,?:0K?7Y8JM+&*O3ES*LL3*;K*JW\4U.]MK.S*^K8?V+P_ ML*7U=TO8^P]G'V/LU]GV:2C;R:MOI?4_,_PA_P`$>_\`@FI\/O%WA;Q[X'_8 MW^$'AGQCX'\2Z+XN\)^(-,T_5(K_`$;Q%X=OH=4T75K1GU:6-;K3]1MH+F!W MB=59""C!C7Z2&%]FS:""FT_<&&QC(&"!R`0,%0>V!Q6KN31PF&PW,L+0I86,Y4Y2AA MJ5.C"4J>B;C"*O=:2O>ZVL?FYX]_X)$_\$W?BIXW\7?$OXC?L>_"+Q9X\\>> M(=6\6>+_`!-JNG:G)J&O>(]=O9M0U;5;QHM6BB-S>WD\DTQCBB5F;.T=!]5? M`#]FKX(?LL^!5^&'[/?PQ\,?"?X>C7-4\2GPIX4MY;?3/[>UA+>+4M4"W$\\ MBW-]':6WVD;VC+0IY87#%O>:*VKYSG&+PM/!8O-LSQ>#I-.GA<3CL56P]-P7 M+3<*$ZKI1]G"U.G:"Y8)16B%2P6#H59UJ&$PU"K4OSU*-&G3G+F=Y)SC%2:D MVV[MW;9#L;T_4?XU#<6BS1F(`;7!5RP5B492C###!W(S+@Y7D[E9Z3.AI/7K9J_E*UU;9IV5[IGY4_M(_P#!%/\`X)J?M5:U<>*OBI^R M]X/LO&5W++<7OC#X8WVM_"/7]1N;B19;BYUB;X=:CX=L=>NYG56EO-;T_4+J M5MQ>3+'/@7P]_P"#-P MCQR0&_\`#EUXIM=#UFT1DQ)INM:=J-E<*<31-@5^Z=%?1T.,.+,-AE@\/Q/Q M!1PJCR*A3S?'PI1II35*OMIY7@)5>9S>#_"W@+PEHRM%I?A;P7H M&E>%_#FG0,=QCL-$T6"RTRT#/\TGE6B[\`G,VZ8]TJD'D=O;VJ2BOG9.4YSJ M3E*=2I)SG.2044 144BPHHHH`****`"BBB@#_]D_ ` end EX-99.02 5 mar0104-ex9902.htm exhibits

 

EXHIBIT 99.2

 

Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com 

 

1 March 2004

 

Shire Pharmaceuticals Group plc (the “Company”)

The Company announces that it was notified on 27 February 2004 under Sections 198 to 202 of the Companies Act that on 26 February 2004 Franklin Resources, Inc. and its affiliates had holdings managed on behalf of investment clients of 66,766,848 ordinary shares of £0.05p each in the capital of the Company. These holdings represent 13,9413 per cent of the issued ordinary share capital of the Company.

T May

Company Secretary

For further information please contact:

Investor Relations

Cléa Rosenfeld           +44 1256 894 160

Notes to editors

Shire Pharmaceuticals Group plc

7

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently has a range of projects and products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com

8

-----END PRIVACY-ENHANCED MESSAGE-----